Benzinga · Sep 18, 2026
Truist Securities Maintains Buy on DexCom, Raises Price Target to $102
Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.
NASDAQ · DXCM
DexCom, Inc.
Healthcare · Medical - Devices
$89.35
Up+$1.42 (+1.61%)
Updated Sep 20, 2026, 4:06 PM
SID Score
7.0/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 26.96B
- P/E ratio
- 37.41
- Dividend yield
- 0.00%
- 52-week range
- $56.72 – $92.59
- Volume
- 14.58M
- Avg. volume
- 6.48M
Price performance
DXCM price history
1M range · 19 trading sessions · Daily adjusted prices
DXCM closed at $89.35 after 19 trading sessions, down 1.88% for the selected period.
- Last close
- $89.35
- Period change
- -1.88%
- Period low
- $83.03
- Period high
- $91.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $87.825 | $89.92 | $87.39 | $89.35 | 14.58M |
| Sep 17, 2026 | $87.54 | $88.26 | $87.17 | $87.93 | 2.82M |
| Sep 16, 2026 | $86.05 | $88.79 | $86.05 | $87.34 | 3.62M |
| Sep 15, 2026 | $84.04 | $87.36 | $83.255 | $86.45 | 5.96M |
| Sep 14, 2026 | $83.92 | $84.98 | $83.76 | $84.68 | 2.54M |
| Sep 11, 2026 | $84.65 | $85.815 | $82.83 | $83.03 | 2.55M |
| Sep 10, 2026 | $83.27 | $84.815 | $82.29 | $84.51 | 3.54M |
| Sep 9, 2026 | $83.93 | $85.16 | $82.795 | $83.88 | 4.18M |
| Sep 8, 2026 | $86.59 | $86.75 | $84.24 | $84.53 | 8.22M |
| Sep 4, 2026 | $88.78 | $89.00 | $87.65 | $87.90 | 2.36M |
| Sep 3, 2026 | $89.73 | $91.00 | $89.05 | $89.71 | 1.68M |
| Sep 2, 2026 | $90.03 | $91.90 | $89.5425 | $89.69 | 1.92M |
| Sep 1, 2026 | $90.83 | $92.335 | $89.91 | $90.14 | 2.15M |
| Aug 31, 2026 | $90.00 | $91.18 | $89.09 | $91.06 | 3M |
| Aug 28, 2026 | $89.805 | $90.84 | $88.825 | $90.82 | 2.55M |
| Aug 27, 2026 | $88.37 | $90.43 | $87.60 | $89.29 | 3.03M |
| Aug 26, 2026 | $88.17 | $89.76 | $87.51 | $88.96 | 3.82M |
| Aug 25, 2026 | $90.731 | $91.14 | $88.78 | $89.16 | 4.11M |
| Aug 24, 2026 | $92.30 | $92.59 | $91.03 | $91.06 | 4.45M |
Latest DXCM news
The latest Smart Investors Daily articles mentioning DXCM.
Stock researchCompany · Overview
DXCM research
Overview
Company profile and research snapshot.
Company profile
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $85.22
- Implied upside
- —
- Analysts
- 37
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | TD Cowen | Buy | — |
| Sep 18, 2026 | Truist Securities | Buy | — |
| Aug 4, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Canaccord Genuity | Buy | — |
| Jul 31, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 18, 2026
TD Cowen Reiterates Buy on DexCom, Maintains $95 Price Target
TD Cowen analyst Joshua Jennings reiterates DexCom (NASDAQ:DXCM) with a Buy and maintains $95 price target.
Yahoo · Sep 16, 2026
Dexcom gives CFO Jereme Sylvain expanded role
Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.
Yahoo · Sep 14, 2026
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
SAN DIEGO, September 14, 2026--Dexcom Promotes Jereme Sylvain to Chief Operating Officer
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
